Targeting Non-BET Bromodomains: Emerging Opportunities in Drug Discovery
Journal of Medicinal Chemistry · 11.12.2025 · 68 (23) · 24730-24758
DOI: 10.1021/acs.jmedchem.5c01162 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.11.2025. Verfasst von Huili Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizho…. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 142 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Independent Research Project of the State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Med…, Guizhou Provincial Basic Research Program.
Abstract (Originalsprache)
Bromodomains, epigenetic “readers” of acetylated lysine marks, represent promising therapeutic targets. The clinical limitations of BET inhibitors, together with growing insights into the distinct functions of non-BET members (e.g., ATAD2, CBP/p300, and BRD7/9), highlight the importance of pursuing their pharmacological potential. This Perspective examines recent medicinal chemistry advances in the development of non-BET bromodomain inhibitors, focusing on structure-guided strategies to address selectivity challenges within conserved KAc-binding pockets. Key topics include: (1) the structural and functional diversity of non-BET bromodomains in oncology, inflammation, and metabolic diseases; (2) innovative design strategies, such as allosteric covalent modulation and the development of PROTACs and other heterobifunctional molecules; and (3) preclinical/clinical progress of leads targeting CBP/p300, BRD7/9, and SMARCA2/4. Pharmacokinetic challenges (e.g., blood–brain barrier penetration, tissue-specific delivery) and opportunities in AI-driven discovery and nonepigenetic synergies are evaluated. By integrating mechanistic insights with medicinal chemistry breakthroughs, this Perspective aims to inform the rational development of selective non-BET bromodomain modulators with enhanced therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Gui'an New District, Guiyang, Guizhou 561113, P.…
- State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Gui'an New District, Guiyang, Guizhou 561113, P.R. China.
Förderung
- National Natural Science Foundation of China
- the Independent Research Project of the State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Med…
- Guizhou Provincial Basic Research Program
- Science and Technology Fund of Guizhou Provincial Health Commission
- the Guiyang Science and Technology Program
- the Guizhou Provincial Department of Education
Zitieren
APA
Li, H., Jiang, F., Sun, Q., Huang, J., Chen, X., He, D., & Shen, X. (2025). Targeting Non-BET Bromodomains: Emerging Opportunities in Drug Discovery. Journal of Medicinal Chemistry, 68(23), 24730-24758. https://doi.org/10.1021/acs.jmedchem.5c01162
Vancouver
Li H, Jiang F, Sun Q, Huang J, Chen X, He D, et al. Targeting Non-BET Bromodomains: Emerging Opportunities in Drug Discovery. Journal of Medicinal Chemistry. 2025;68(23):24730-24758. doi:10.1021/acs.jmedchem.5c01162
BibTeX
@article{Li2025,
author = {Li, Huili and Jiang, Fei and Sun, Quan and Huang, Jiandong and Chen, Xianggui and He, Dandan and Shen, Xiangchun},
title = {Targeting Non-BET Bromodomains: Emerging Opportunities in Drug Discovery},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {23},
pages = {24730--24758},
doi = {10.1021/acs.jmedchem.5c01162}
}
EUVIMED